These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2817862)

  • 1. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).
    Chirgwin K; Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1634-5. PubMed ID: 2817862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in-vitro activity of clarithromycin and other macrolides against the type strain of Chlamydia pneumoniae (TWAR).
    Ridgway GL; Mumtaz G; Fenelon L
    J Antimicrob Chemother; 1991 Feb; 27 Suppl A():43-5. PubMed ID: 1827101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.
    Welsh L; Gaydos C; Quinn TC
    Antimicrob Agents Chemother; 1996 Jan; 40(1):212-4. PubMed ID: 8787907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro drug susceptibility of Chlamydia sp. strain TWAR.
    Kuo CC; Grayston JT
    Antimicrob Agents Chemother; 1988 Feb; 32(2):257-8. PubMed ID: 2966609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of garenoxacin against Chlamydia spp.
    Donati M; Pollini GM; Sparacino M; Fortugno MT; Laghi E; Cevenini R
    J Antimicrob Chemother; 2002 Sep; 50(3):407-10. PubMed ID: 12205067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.
    Welsh LE; Gaydos CA; Quinn TC
    Antimicrob Agents Chemother; 1992 Feb; 36(2):291-4. PubMed ID: 1318677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection and the antibiotic susceptibility analysis of mycoplasma and chlamydia in urogenital tract infections of 327 cases patients with tubal infertility].
    Zhou Y; Xu XL; Wang CP; Zhou M; Zeng XH
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Jun; 25(3):201-4. PubMed ID: 21977592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines.
    Samra Z; Rosenberg S; Soffer Y; Dan M
    Diagn Microbiol Infect Dis; 2001 Mar; 39(3):177-9. PubMed ID: 11337185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae.
    Miyashita N; Fukano H; Yoshida K; Niki Y; Matsushima T
    J Antimicrob Chemother; 2003 Sep; 52(3):497-9. PubMed ID: 12917246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.
    Kuo CC; Jackson LA; Lee A; Grayston JT
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2669-70. PubMed ID: 8913488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.
    Hammerschlag MR; Qumei KK; Roblin PM
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1573-4. PubMed ID: 1324650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in-vitro antibiotic susceptibility of Chlamydia pneumoniae.
    Fenelon LE; Mumtaz G; Ridgway GL
    J Antimicrob Chemother; 1990 Dec; 26(6):763-7. PubMed ID: 2081718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae.
    Miyashita N; Fukano H; Niki Y; Matsushima T
    J Antimicrob Chemother; 2001 Sep; 48(3):403-5. PubMed ID: 11533006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of six macrolides, clindamycin and tetracycline on Streptococcus pneumoniae with different penicillin susceptibilities.
    Poulsen RL; Knudsen JD; Petersen MB; Fuursted K; Espersen F; Frimodt-Møller N
    APMIS; 1996 Mar; 104(3):227-33. PubMed ID: 8611198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia.
    Roblin PM; Montalban G; Hammerschlag MR
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1588-9. PubMed ID: 7979292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.
    Riska PF; Kutlin A; Ajiboye P; Cua A; Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3586-90. PubMed ID: 15328134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility of Chlamydia pecorum to macrolides, tetracyclines, quinolones and beta-lactam.
    Pudjiatmoko ; Fukushi H; Ochiai Y; Yamaguchi T; Hirai K
    Microbiol Immunol; 1998; 42(1):61-3. PubMed ID: 9525782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.
    Boswell FJ; Andrews JM; Ashby JP; Fogarty C; Brenwald NP; Wise R
    J Antimicrob Chemother; 1998 Dec; 42(6):703-9. PubMed ID: 10052892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine).
    Hoppe JE; Bryskier A
    Antimicrob Agents Chemother; 1998 Apr; 42(4):965-6. PubMed ID: 9559823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.
    Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1515-6. PubMed ID: 9624507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.